

Telomere length and neurodevelopmental outcomes among children exposed and not exposed to HIV in Kenya

Jillian Neary,¹ Tiffany D Pan,¹ Irene Njuguna,^{1,2} Maureen King'e,³ Fiona McBride,¹ Daniel Matemo,² Alvin Onyango,³ Michelle Bulterys,¹ Prestone Owiti,³ Celestine Adogo,² Dalton Wamalwa,³ Sarah Benki-Nugent,¹ Dan T A Eisenberg,^{*1} Grace John-Stewart^{*1}

¹University of Washington, Seattle, WA, USA, ²Kenyatta National Hospital, Nairobi, Kenya, ³University of Nairobi, Nairobi, Kenya, ^{*}Co-last authors


Background

- Telomere length (TL) is an important biomarker of biological aging.¹
- TL shortens from cell division, inflammation, and oxidative stress.²
- Childhood is a time of increased telomere attrition³ and changes in childhood TL are thought to persist into adulthood.⁴
- There is some evidence that CHEU may have shorter TL⁵ and poorer neurodevelopmental outcomes compared to CHUU.⁶
- Shorter TL was associated with lower neurodevelopmental scores in some studies while others found no association.⁷⁻⁹

Objective: To determine the association between 6-week telomere length (TL) and repeated neurodevelopmental scores among children who are HIV exposed and uninfected (CHEU) and children who are HIV unexposed and uninfected (CHUU)

Methods

- Parent study:** HOPE study enrolled 1,000 CHEU and 1,000 CHUU at 6 weeks and followed through 36 months of age
- Population:** 250 CHEU and 250 CHUU in HOPE who were retained through 24 months from 6 clinics in Nairobi and Western Kenya
- Design:** Prospective cohort study
- Laboratory methods:** TL was measured from dried blood spots using a modified version¹¹ of the monochrome multiplex qPCR assay¹²
- Exposure:** Relative infant TL, the ratio of the amount of telomeric DNA (T) to the single copy gene (S) z-score at 6 weeks
- Outcomes:** Malawi Developmental Assessment Tool (MDAT) social, language, fine motor, and gross motor scores¹³



- Statistical methods:**
 - Linear mixed effects models with clinic as a random effect
 - Adjusted for infant age, infant sex, maternal age and education
 - Benjamini-Hochberg approach to adjust for multiple comparisons
- Analysis plan was pre-registered prior to conducting the analysis


Results

Table 1. Characteristics of CHEU and CHUU with TL at 6 weeks

	n(%) or Median (IQR)	
	CHEU N=250	CHUU N=250
Age at sample collection (weeks)	6.6 (6.0, 7.9)	6.6 (6.0, 7.6)
Female (REF: Male)	130 (52%)	125 (50%)
Birth weight (kg)	3.2 (3.0, 3.5)	3.3 (3.0, 3.6)
Preterm birth (<37 weeks gestation)	7 (2.8%)	7 (2.8%)
Exclusively breastfed at 6 weeks	246 (99%)	238 (95%)
Maternal age (years)	31 (28, 36)	26 (23, 30)
Paternal age (years)	37 (32, 42)	31 (28, 35)
Maternal years of education	8 (8, 12)	12 (9, 12)
Moderate-to-severe food insecurity	63 (25%)	24 (10%)

- Compared to CHUU, CHEU were more frequently exclusively breastfed and had older parents, mothers with fewer years of education, and households with food insecurity (Table 1).
- Most mothers with HIV were on ART prior to and during pregnancy (88% and 99%, respectively).
 - During pregnancy, 76% of mothers of CHEU were on dolutegravir-based regimens.

Figure 1. Adjusted models evaluating the association between 6-week TL and neurodevelopmental outcomes



*p-value<0.05

- In stratified analyses of CHEU and CHUU, TL z-score was not correlated with neurodevelopmental scores


Conclusions

- In this large cohort of CHEU and CHUU, TL at 6 weeks was not significantly associated with neurodevelopmental outcomes measured at multiple timepoints.
- There is evidence that TL is associated with age-related health outcomes. Further analyses to assess whether TL decline between 6 weeks and 24 months or TL at 24 months correlate with child neurodevelopmental scores is warranted.

Acknowledgements

We thank the study participants, clinical research team, and administrative team for their dedication and support.

Funding: R33HD103079, T32 AI07140, P2C HD042828



References:

- Vaiserman et al. *Front Genet* 2021; 2. Rizvi et al. *Curr Aging Sci* 2015; 3. Cowell et al. *Psychoneuroendocrinology* 2021; 4. Martens et al. *EBioMedicine* 2021; 5. Shiao et al. *J Acquir Immune Defic Syndr*. 2018; 6. McHenry *J Int AIDS Soc* 2019; 7. Wedderburn *Lancet Child Adolesc Health* 2022; 8. Pham et al. *Int J Mol Sci* 2022; 9. Naudé et al. *J Affect Disord* 2023; 10. Campos-Sánchez et al. *Eur Child Adolesc Psychiatry* 2024; 11. Rej et al. *American Journal of Human Biology* 2021; 12. Cawthorn et al. *Nucleic Acids Res* 2009; 13. Gladstone *PLoS Med* 2010